BZ vs RCUS

For growth investors, Kanzhun Limited (BZ) is the stronger pick with 23.

6% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Kanzhun Limited (BZ) offers the better valuation at 27. 2x trailing P/E (1. 6x forward), making it the more compelling value choice. Analysts rate Kanzhun Limited (BZ) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -15. 0%, compared to -61. 2% for Kanzhun Limited (BZ). Over 10 years, the gap is even starker: RCUS returned +39. 9% versus BZ's -61. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kanzhun Limited (BZ) is the lower-risk stock at 1.

05β versus Arcus Biosciences, Inc. 's 1. 86β — meaning RCUS is approximately 78% more volatile than BZ relative to the S&P 500. On balance sheet safety, Kanzhun Limited (BZ) carries a lower debt/equity ratio of 2% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kanzhun Limited (BZ) is pulling ahead at 23.

6% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Kanzhun Limited grew EPS 43. 9% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kanzhun Limited (BZ) is the more profitable company, earning 21.

5% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 21. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BZ leads at 15. 9% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BZ: 99.

0% to $28. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kanzhun Limited (BZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

05)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BZ: -61. 2%, RCUS: +39. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BZ (Industrials) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BZ is a mid-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.